Pradžia › Dermatomiozitas
Dermatomiozitas klinikiniai tyrimai JAV ieško dalyvių
26 tyrimai dėl Dermatomiozitas ieško dalyvių vietose visoje Jungtinėse Valstijose.
Miestai su daugiausia tyrimų
- Durham, NC8 tyrimai
- Washington, DC7 tyrimai
- New York City, NY5 tyrimai
- Pittsburgh, PA5 tyrimai
- Houston, TX5 tyrimai
- Boston, MA5 tyrimai
- Philadelphia, PA4 tyrimai
- Baltimore, MD4 tyrimai
- Miami, FL4 tyrimai
- Cleveland, OH3 tyrimai
- Kansas City, KS3 tyrimai
- Jacksonville, FL3 tyrimai
- Aurora, CO3 tyrimai
- New Haven, CT3 tyrimai
- Phoenix, AZ3 tyrimai
Pagal valstiją
- Arizona4 tyrimai
- Florida7 tyrimai
- Ilinoisas3 tyrimai
- Kalifornija9 tyrimai
- Kanzasas4 tyrimai
- Koloradas4 tyrimai
- Konektikutas3 tyrimai
- Masčusetsas5 tyrimai
- Merilendas9 tyrimai
- New York6 tyrimai
- North Carolina8 tyrimai
- Ohio5 tyrimai
- Pennsylvania7 tyrimai
- Texas6 tyrimai
Nesenai atnaujinti tyrimai
Oficialus tyrimo tekstas (anglų kalba)
FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
Renkami dalyviai2 fazė
Amžius nuo 18 iki 60 · Visoms lytims · Atnaujinta 2026-10-02 · NCT07111065Environmental Risk Factors for the Anti-synthetase Syndrome
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 2 iki 100 · Visoms lytims · Atnaujinta 2026-09-28 · NCT01276470A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-24 · NCT06455449Natural History of Inflammatory Muscle Diseases
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 2 iki 120 · Visoms lytims · Atnaujinta 2026-09-24 · NCT05738824Adult and Juvenile Myositis
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 2 iki 100 · Visoms lytims · Atnaujinta 2026-09-24 · NCT00017914Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT03816345RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Renkami dalyviai2/3 fazė
Amžius nuo 6 iki 75 · Visoms lytims · Atnaujinta 2026-09-17 · NCT06154252A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Renkami dalyviai1 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-15 · NCT06916806A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-15 · NCT05895786A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Renkami dalyviai1 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-09-10 · NCT07085104FT839 in Autoimmune Diseases
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-02 · NCT07800871A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-25 · NCT06698796Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-25 · NCT07486869Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Renkami dalyviai1/2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-07-27 · NCT07089121Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Renkami dalyviai1 fazė
Amžius nuo 18 iki 85 · Visoms lytims · Atnaujinta 2026-07-22 · NCT06371417A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-14 · NCT07115745Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-09 · NCT07138898Intralesional Injection of STS in Treatment of Calcinosis
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-05 · NCT06672822Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)
Renkami dalyviai2/3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-27 · NCT07160205Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-30 · NCT02945345Rheumatology Patient Registry and Biorepository
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 18 iki 99 · Visoms lytims · Atnaujinta 2026-02-13 · NCT04402086A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-11 · NCT07403188MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Renkami dalyviaiStebimasis tyrimas
Amžius 7 ir vyresni · Visoms lytims · Atnaujinta 2026-01-28 · NCT07374107Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
Renkami dalyviai2 fazė
Amžius nuo 18 iki 89 · Visoms lytims · Atnaujinta 2025-10-08 · NCT06857240Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
Renkami dalyviai1 fazė
Amžius nuo 25 iki 72 · Visoms lytims · Atnaujinta 2025-05-21 · NCT06298019Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.